Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation

Abstract

LNCaP prostatic cancer cells are characterized by having a PTEN mutation, low levels of type 1 insulin-like growth factor receptor (IGF-IR) and no IRS-1, one of the major substrates of the IGF-IR. The absence of IRS-1, an activator of PI3-kinase, is compensated in these cells by the mutation in PTEN, an inhibitor of PI3-kinase. However, IGF-IR signaling in the absence of IRS-1 can cause cell differentiation and growth arrest. We hypothesized that these three characteristics may not be unrelated, specifically that, together, they may favor the metastatic spread of prostatic cancer cells without decreasing their growth potential. In support of this hypothesis, we report here that: (1) IRS-1 expression increases cell adhesion and decreases cell motility; (2) over-expression of the IGF-IR, in the absence of IRS-1, causes growth arrest and (3) a combination of IGF-IR and IRS-1 restores the transformed phenotype of LNCaP cells. These findings suggest a mechanism by which prostatic cancer cells can achieve metastatic potential without interfering with their growth potential.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Angelloz-Nicoud P and Binoux M . 1995 Endocrinology 136: 5485–5492

  • Baserga R, Prisco M and Hongo A . 1999 Contemporary Endocrinology The IGF System Rosenfeld R and Roberts Jr C edHumana Press, Inc Totawa, NJ pp 329–353

  • Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, Rhim JS, Linchan WM and Topalian SI . 1997 Cancer Res 57: 995–1002

  • Brooks PC, Klemke RL, Schoen S, Lewis JM, Schwartz MA and Cheresh DA . 1997 J Clin Invest 99: 1390–1398

  • Burfeind P, Chernicky CL, Rininsland F, Ilan J and Ilan I . 1996 Proc Natl Acad Sci USA 93: 7263–7268

  • Carson JP, Kulik G and Weber MJ . 1999 Cancer Res 59: 49–53

  • Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennenkens CH and Pollak M . 1998 Science 279: 563–566

  • Cohen P, Peehl DM, Lamson G and Rosenfeld RG . 1991 J Clin Endocrinol Metabol 73: 401–407

  • D'Ambrosio C, Keller SR, Morrione A, Lienhard GE, Baserga R and Surmacz E . 1995 Cell Growth Differ 6: 557–562

  • Davies MA, Koul D, Dhesi H, Berman R, McDonnell TJ, McConkey D, Yung WK and Steck PA . 1999 Cancer Res 59: 2551–2556

  • Dunn SE, Ehrlich M, Sharp NJH, Reiss K, Solomon G, Hawkins R, Baserga R and Barrett JC . 1998 Cancer Res 58: 3353–3361

  • Feshchenko EA, Shore SK and Tsygankov AY . 1999 Oncogene 18: 3703–3715

  • Furnari FB, Hong L, Huang HJS and Cavenee WK . 1997 Proc Natl Acad Sci USA 94: 12479–12484

  • Furnari FB, Huang HJS and Cavenee WK . 1998 Cancer Res 58: 5002–5008

  • Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC and Chung LWK . 1992 Cancer Res 52: 1598–1605

  • Guilherme A and Czech MP . 1998 J Biol Chem 273: 33119–33122

  • Guilherme A, Torres K and Czech MP . 1998 J Biol Chem 273: 22899–22903

  • Guvakova MA and Surmacz E . 1997 Exp Cell Res 231: 149–162

  • Huynh H, Seyam RM and Brock GB . 1998 Cancer Res 58: 215–218

  • Jones JI, Prevette T, Cockerman A and Clemmons DR . 1996 Proc Natl Acad Sci USA 93: 2482–2487

  • Li DM and Sun H . 1998 Proc Natl Acad Sci USA 95: 15406–15411

  • Li J, Simpson L, Takahashi M, Miliaresis C, Myers MP, Tonks N and Parsons R . 1998 Cancer Res 58: 5667–5672

  • Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Ouc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann C, Tycko B, Hibshoosh H, Wigler MH and Parsons R . 1997 Science 275: 1943–1947

  • Mantzoros CS, Tzonou A, Signorelo LB, Stampler M, Trichopoulos D and Adami HO . 1997 Brit J Cancer 76: 1115–1118

  • Myers Jr MG, Grammar TC, Wang LM, Sun XJ, Pierce JH, Blenis J and White MF . 1994 J Biol Chem 269: 28783–28789

  • Myers Jr MG, Mendez R, Shi P, Pierce JH, Rhoads R and White MF . 1998 J Biol Chem 273: 26908–26914

  • Ogawa W, Matozaki T and Kasuga M . 1998 Mol Cell Biochem 182: 13–22

  • Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B and Baserga R . 1999 Mol Cell Biol 19: 7203–7215

  • Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D and Baserga R . 1993 Cancer Res 53: 1102–1106

  • Plymate SR, Bae VL, Maddison L, Quinn LS and Ware JL . 1997 Endocrinology 138: 1728–1735

  • Reiss K, D'Ambrosio C, Tu X, Tu C and Baserga R . 1998 Clinical Cancer Res 4: 2647–2655

  • Reiss K, Yumet G, Shan S, Huang Z, Alnemri E, Srinivasula SM, Wang JY, Morrione A and Baserga R . 1999 J Cell Physiol 181: 124–135

  • Romano G, Prisco M, Zanocco-Marani T, Peruzzi F, Valentinis B and Baserga R . 1999 J Cell Biochem 72: 294–310

  • Sell C, Rubini M, Rubin R, Liu JP, Efstratiadis A and Baserga R . 1993 Proc Natl Acad Sci USA 90: 11217–11221

  • Soos G, Jones RF, Haas GP and Wang CY . 1997 Anticancer Res 17: 4253–4258

  • Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DHF and Tavtigian SV . 1997 Nature Genetics 15: 356–362

  • Tamura M, Gu J, Matsumoto K, Aota S, Parsons R and Yamada K . 1998 Science 280: 1614–1617

  • Tamura M, Gu J, Danen EHJ, Takino T, Miyamoto S and Yamada KM . 1999 J Biol Chem 274: 20693–20703

  • Tanaka S, Ito T and Wands JR . 1996 J Biol Chem 271: 14610–14616

  • Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC and Chung LWK . 1994 Cancer Res 54: 2577–2581

  • Valentinis B, Reiss K and Baserga R . 1998 J Cell Physiol 176: 648–657

  • Valentinis B, Morrione A, Peruzzi F, Prisco M, Reiss K and Baserga R . 1999a Oncogene 18: 1827–1836

  • Valentinis B, Romano G, Peruzzi F, Morrione A, Prisco M, Soddu S, Cristofanelli B, Sacchi A and Baserga R . 1999b J Biol Chem 274: 12423–12430

  • Vuori K and Ruoslahti E . 1994 Science 266: 1576–1578

  • White MF . 1998 Recent Prog Horm Res 53: 119–138

  • Wick W, Furnari FB, Naumann U, Cavenee WK and Weller M . 1999 Oncogene 18: 3936–3943

  • Wu X, Senechal K, Neshat MS, Whang YE and Sawyers CL . 1998 Proc Natl Acad Sci USA 95: 15587–15591

  • Zheng B and Clemmons DR . 1998 Proc Natl Acad Sci USA 95: 11217–11222

Download references

Acknowledgements

This work is supported by Grants CA 53484 and CA 78890 from the National Institutes of Health.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reiss, K., Wang, JY., Romano, G. et al. IGF-I receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19, 2687–2694 (2000). https://doi.org/10.1038/sj.onc.1203587

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203587

Keywords

This article is cited by

Search

Quick links